Le Lézard
Classified in: Health, Science and technology
Subject: Personnel

SAMDI Tech's Dr. Zachary Gurard-Levin Elected to Society of Laboratory Automation and Screening (SLAS) Board


SAMDI Tech, Inc., the industry's leading provider of label-free drug discovery solutions, today announced that Chief Scientific Officer Zachary Gurard-Levin, Ph.D., has been elected to the board of directors for the Society of Laboratory Automation and Screening (SLAS). The board's diverse group includes leaders from academic, industry and government research, as well as developers and providers of laboratory automation technologies.

"SLAS has had a significant impact on my scientific growth and development," Dr. Gurard-Levin said. "I appreciate the society's power to promote good science and unite researchers from different technical backgrounds and geographic locations. I look forward to providing a fresh perspective to enable and support SLAS' mission while providing resources for our diverse, international community as we construct the labs of the future."

Dr. Gurard-Levin is one of three new board members elected who are responsible for strategic leadership of the society and advising on its future direction and its programs. He will begin a three-year term in January 2023.

"Dr. Gurard-Levin not only co-developed the SAMDI technology as a high-throughput, label-free solution for drug discovery research, he also brings his in-depth broad scientific and business expertise to the board," said SAMDI Tech CEO Emilio Cordova, Ph.D. "He brings a unique voice to the board for all members ? from young scientists to experienced executives ? to support innovation across the fields of life and health sciences."

About SAMDI Tech, Inc.

SAMDI Tech, Inc. delivers better, faster assay development, high-throughput screening and hit-to-lead solutions for early-stage drug discovery. Our highly skilled team of biochemistry experts believes in quality results and uses proprietary industry-leading, label-free SAMDI (Self-Assembled Monolayer Desorption Ionization) technology to deliver decision-making data for diverse targets and analytes. Learn more about SAMDI Tech's comprehensive drug discovery solutions at www.samditech.com.


These press releases may also interest you

at 02:22
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024 First Quarter 2024 Total revenue increased 19 per cent, 20 per cent at constant exchange rates, (CER)1, to SEK 6,256 M (5,239)Haematology revenue...

at 02:08
Homestyler, a leading all-in-one 3D Design platform and creative community for global designers invested by Easyhome New Retail Group and Alibaba Group, successfully hosted the Homestyler Global Partners Conference and Gorgeous Home Imported Brand...

at 02:05
AstraZeneca: Revenue and EPS summary     Q1 2024 % Change $m Actual CER1 - Product Sales 12,177 15 18 - Alliance Revenue   457 59 59...

at 02:00
ICEYE, a global leader in satellite-powered disaster management solutions, has announced a new data collaboration with Juniper Re, LLC ("Juniper Re"), the dynamic reinsurance broking arm and indirect subsidiary of BRP Group, Inc. . Juniper Re will...

at 02:00
CACI is delighted to announce that its Cygnum software will be used by the Environment Agency as a logistics planning tool to schedule its workforce and assets in the preparation of and response to incidents across England ranging from small...

at 02:00
PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a target-exclusive research and...



News published on and distributed by: